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Proper regulation of the phosphoinositide 3-kinase–Akt
pathway is critical for the prevention of both insulin re-
sistance and tumorigenesis. Many recent studies have char-
acterized a negative feedback loop in which components
of one downstream branch of this pathway, composed of
the mammalian target of rapamycin and ribosomal S6
kinase, block further activation of the pathway through
inhibition of insulin receptor substrate function. These ﬁnd-
ings form a novel basis for improved understanding of the
pathophysiology of metabolic diseases (e.g., diabetes and
obesity), tumor syndromes (e.g., tuberous sclerosis complex
and Peutz-Jegher’s syndrome), and human cancers.
 
Growth factors of the insulin family, including insulin, insulin-
like growth factor (IGF) I, and IGF-II, are critical regulators of
cell growth, survival, and metabolism. These molecules exert
their effects on cell physiology through activation of insulin/
IGF-I receptor tyrosine kinases (RTKs) on the surface of re-
sponsive cells. Once activated, these RTKs autophosphorylate,
creating phosphotyrosine binding sites for the insulin receptor
substrate (IRS) family of scaffolding proteins, among others. IRS
proteins are subsequently phosphorylated by the insulin/IGF-I
RTKs on several tyrosine residues. The resulting phosphoty-
rosines initiate signaling cascades by acting as binding sites for
proteins containing src homology 2 domains, including the p85
regulatory subunit of class I phosphoinositide 3-kinase (PI3K).
IRS-mediated activation of PI3K at the plasma membrane leads to
its generation of the lipid second messenger phosphatidylinositol-
3,4,5-trisphosphate (PIP
 
3
 
), which recruits a subset of proteins
with pleckstrin homology domains. Among these is the Ser/
Thr kinase Akt (also known as protein kinase B), which is acti-
vated upon recruitment to the plasma membrane. Activated Akt,
through subsequent phosphorylation of several downstream
targets, is primarily responsible for the ability of the insulin
family of growth factors to stimulate cell growth, survival, and
glucose uptake (for recent reviews on insulin signaling see Saltiel
and Kahn, 2001; White, 2002).
Resistance, or unresponsiveness, to insulin is associated
with a wide variety of human disorders, including type 2 diabetes,
obesity, and cardiovascular disease. This fact has lead many
laboratories to focus their efforts on characterizing molecular
events that contribute to the desensitization of cells to insulin.
A primary mechanism that has surfaced from these studies is the
inhibition of IRS protein function through the phosphorylation of
serine residues, degradation, and/or decrease in expression of
serine that disconnect the insulin receptor from PI3K–Akt
activation (for reviews see Saltiel and Kahn, 2001; White,
2002). Many distinct pathways have been implicated in the
down-regulation of IRS-1 and IRS-2. For instance, adipose-
derived molecules, such as tumor necrosis factor 
 
 
 
 (TNF-
 
 
 
)
and free fatty acids (FFAs), stimulate an inhibitory phosphory-
lation of mouse IRS-1 by c-Jun NH
 
2
 
-terminal kinase (JNK;
Hotamisligil et al., 1996; Aguirre et al., 2000; Hirosumi et al.,
2002). Interestingly, another mechanism of IRS-1 inhibition
stems from prolonged exposure to insulin itself and requires
activation of the PI3K–Akt pathway (Smith et al., 1995; Rui et
al., 2001). Recently, activation of the mammalian target of
rapamycin (mTOR) branch downstream of the PI3K–Akt path-
way has emerged as the critical event in rendering IRS-1 and
IRS-2 unresponsive to insulin/IGF-I. This mTOR-mediated
negative feedback loop and its physiological relevance to meta-
bolic disorders and, perhaps, tumorigenesis are the focus of
this review.
 
mTOR and insulin resistance
 
TOR proteins are Ser/Thr kinases with highly conserved homo-
logues that are found in all eukaryotes (Schmelzle and Hall,
2000). In mammals, the two best-characterized targets of
mTOR are the ribosomal S6 kinases (S6K1 and S6K2) and the
eukaryotic initiation factor 4E (eIF4E)–binding protein 1 (4E-
BP1). mTOR activity leads to S6K1/2 phosphorylation and ac-
tivation and to 4E-BP1 phosphorylation and release from the
cap-dependent translation initiation factor eIF4E. These two
events, likely combined with other mTOR targets, lead to an
increase in ribosomal biogenesis and the selective translation
of specific mRNA populations. This ability to increase the pro-
tein synthesis capacity of the cell is responsible, at least in part,
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for the ability of TOR proteins to drive cell growth and prolif-
eration (for review see Fingar and Blenis, 2004).
Full activation of the mTOR pathway requires signals
from both nutrients (e.g., amino acids and glucose) and growth
factors. Although the mechanism by which amino acids are
sensed by TOR proteins is unknown, their presence is essential
for basal activation of mTOR signaling, as well as for further
stimulation by growth factors (Hara et al., 1998). Interestingly,
amino acids have been shown to modulate insulin signaling
through mTOR-dependent effects on IRS-1 (Takano et al.,
2001; Tremblay and Marette, 2001). In both adipocytes and
myocytes it has been demonstrated that, via mTOR regulation,
excess amino acids attenuate and amino acid starvation stimu-
lates Akt activation and subsequent glucose uptake in response
to insulin. These effects are concomitant with changes in the
state of IRS-1 phosphorylation, localization, and/or degrada-
tion. Therefore, the levels of circulating amino acids and other
nutrients may have a profound effect on the insulin sensitivity
of peripheral tissues, such as fat and skeletal muscle, through
mTOR-mediated regulation of IRS-1 function.
The primary pathway by which most growth factors and
cytokines activate mTOR and its downstream targets appears
to be the PI3K–Akt pathway (for review see Fingar and
Blenis, 2004). As with amino acids, several research groups
have found that PI3K–Akt-mediated activation of mTOR also
leads to attenuation of insulin signaling. Their studies have
demonstrated that activation of the PI3K–Akt–mTOR path-
way in various cell lines by PDGF (Li et al., 1999), TNF-
 
 
 
(Ozes et al., 2001), or insulin itself (Haruta et al., 2000;
Greene et al., 2003; Carlson et al., 2004) leads to IRS-1 and/
or IRS-2 serine phosphorylation and down-regulation. Al-
though all of these studies found that IRS protein phosphory-
lation is sensitive to the mTOR-specific inhibitor rapamycin,
the serine residues that are proposed to be involved vary.
PDGF-mediated inhibition of IRS-1 required the proline-
directed sites S632, S662, and S731 (Li et al., 1999), TNF-
 
 
 
treatment correlated with S632 and S635 phosphorylation
(Ozes et al., 2001), and both amino acids and insulin stimu-
lated S307 phosphorylation (Rui et al., 2001; Greene et al.,
2003; Carlson et al., 2004; all numbering is for mouse IRS-1).
However, S307 (S312 in humans) is the only site demon-
strated to be required for insulin-stimulated IRS-1 down-reg-
ulation (Greene et al., 2003). Although this site was indepen-
dently found to be phosphorylated by JNK in response to
TNF-
 
 
 
 (Aguirre et al., 2000; Hirosumi et al., 2002), JNK
does not appear to be responsible for S307 phosphorylation in
response to insulin (Rui et al., 2001; Greene et al., 2003), and
the identity of the mTOR-dependent kinase that directly phos-
phorylates this site remains unknown.
 
The 
 
TSC
 
 genes and mTOR-dependent 
IRS-1/2 down-regulation
 
Tuberous sclerosis complex (TSC) is a syndrome character-
ized by a pleiotropic array of benign tumors, collectively re-
ferred to as hamartomas, often containing abnormally large
cells (for a recent review see Kwiatkowski, 2003). Although
these tumors rarely become malignant, their presence in vari-
ous tissues gives rise to severe clinical manifestations, includ-
ing neurological disorders, skin lesions, cardiac dysfunction,
and kidney and lung failure. The disease has been mapped to
mutations in either of the two tumor suppressor genes 
 
TSC1
 
,
which encodes the hamartin protein, and 
 
TSC2
 
, which encodes
the tuberin protein.
The hamartin and tuberin proteins form a complex that has
recently been found to act within the pathway leading from
PI3K–Akt activation to mTOR signaling (for review see Man-
ning and Cantley, 2003). The tuberin–hamartin complex po-
tently inhibits TOR-dependent signaling in both flies and mam-
mals (Gao et al., 2002; Goncharova et al., 2002; Kwiatkowski et
al., 2002; Tee et al., 2002), and this inhibition is relieved by Akt-
directed phosphorylation of tuberin (Inoki et al., 2002; Manning
et al., 2002; Potter et al., 2002). Therefore, in response to growth
factors such as insulin, the PI3K–Akt pathway activates mTOR
signaling through phosphorylation and inhibition of tuberin (Fig.
1 A). Interestingly, the responsiveness of TOR proteins to other
signals, such as nutrient and energy availability, also appears to
be dependent on the 
 
TSC
 
 genes (Gao et al., 2002; Inoki et al.,
2003, Shaw et al., 2004). Therefore, homozygous loss of 
 
TSC1
 
or 
 
TSC2
 
 leads to high constitutive activation of mTOR signaling,
as detected in mouse embryonic fibroblasts (MEFs; Jaeschke et
al., 2002; Kwiatkowski et al., 2002; Zhang et al., 2003), in the
tumors of rodent models of TSC (Kenerson et al., 2002; El-
Hashemite et al., 2003a), and in human TSC cells and tumors
(Goncharova et al., 2002; El-Hashemite et al., 2003b).
The study of 
 
TSC1
 
 
 
/
 
 
 
 
 
and 
 
TSC2
 
 
 
/
 
 
 
 MEFs has uncov-
ered a striking inability of serum, PDGF, and, especially, in-
sulin and IGF-I to activate the PI3K–Akt pathway in these
cells (Jaeschke et al., 2002; Kwiatkowski et al., 2002; Zhang
et al., 2003). This strong attenuation of Akt activation is also
seen in 
 
Drosophila melanogaster TSC1
 
 
 
/
 
 
 
 cells and larvae
(Radimerski et al., 2002). The insensitivity of 
 
TSC
 
-deficient
MEFs to PDGF is due to a loss of expression of both PDGF
receptor 
 
 
 
 and PDGF receptor 
 
 
 
 (Zhang et al., 2003). How-
ever, two groups have now characterized the mechanism of
insulin/IGF-I resistance in these MEFs (Harrington et al.,
2004; Shah et al., 2004). They found that the resistance is a
consequence of constitutive down-regulation of IRS-1 and
IRS-2 that is due to sustained and unregulated mTOR signal-
ing. Harrington et al. (2004) found that in the absence of
 
TSC2
 
, both IRS-1 and IRS-2 shift to a slower mobility during
SDS-PAGE, which is generally indicative of an increase in
Ser/Thr phosphorylation, and this shift is blocked by short
(1 h) treatments with rapamycin. This group found that the
mRNA and protein levels of IRS-1 alone are decreased in
 
TSC
 
-deficient MEFs, whereas Shah et al. (2004) found that
the levels and stability of both the IRS-1 and IRS-2 proteins
are decreased in these cells. Importantly, both studies found
that long-term (24 h) treatment of 
 
TSC
 
-deficient MEFs with
rapamycin completely restores IRS-1 protein levels and the
insulin/IGF-I responsiveness of the PI3K–Akt pathway. To-
gether, these studies demonstrate that high levels of constitu-
tive mTOR activity strongly down-regulate insulin/IGF-I sig-
naling through combined effects on IRS-1 expression and
IRS-1 and IRS-2 serine phosphorylation and protein stability. 
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S6K1: closing the loop
 
It is now well established that mTOR signaling is intimately in-
volved in many pathways that lead to insulin resistance through
IRS-1/2 down-regulation. The finding in 
 
Drosophila
 
 that lar-
vae doubly mutant for 
 
dTSC1
 
 and 
 
dS6K
 
 have normal levels of
Akt activity, relative to the attenuated state of 
 
dTSC1
 
 
 
/
 
 
 
 larvae,
was the first suggestion that this feedback mechanism down-
stream of mTOR is likely to be mediated by S6K (Radimerski
et al., 2002). Harrington et al. (2004) have now found that
small interfering RNA knockdown of S6K1 or S6K2 can re-
store the expression of IRS-1 mRNA in 
 
TSC2
 
 
 
/
 
 
 
 MEFs. Fur-
thermore, in overexpression experiments, Shah et al. (2004)
found that a kinase-dead version of S6K1 can block this nega-
tive feedback loop and activate Akt.
Although the mechanism of transcriptional regulation of
IRS-1 by S6K1/2 remains unknown, it appears that the effect of
S6K1 on IRS-1 serine phosphorylation is direct. In in vitro ki-
nase assays, S6K1 directly phosphorylates S302 of mouse IRS-1
(Harrington et al., 2004), a site matching its preferred substrate
recognition motif (Alessi et al., 1996). Furthermore, S302 is
constitutively phosphorylated in 
 
TSC2
 
 
 
/
 
 
 
 MEFs, and this phos-
phorylation is inhibited by treatment with either rapamycin or
S6K1 small interfering RNAs. The results from in vitro binding
assays suggest that phosphorylation of this site by S6K hinders
the ability of IRS-1 to associate with the insulin receptor (Har-
rington et al., 2004). A recent independent study also found that
insulin and IGF-I stimulate mTOR-dependent S302 phosphory-
lation in various cell lines, as well as in skeletal muscle (Giraud
et al., 2004). However, the results of overexpression experi-
ments led this group to conclude that S302 phosphorylation en-
hances, rather than inhibits, insulin signaling. Although addi-
tional experiments are necessary to resolve this discrepancy,
two other research groups have recently provided further evi-
dence that S302 phosphorylation inhibits signaling from IRS-1
(Greene et al., 2004; Werner et al., 2004).
A critical in vivo role for S6K1 in desensitizing tissues to
insulin was demonstrated in a recent study on 
 
S6K1
 
-deficient
mice (Um et al., 2004). The researchers found that these mice
are hypersensitive to insulin and impervious to the obesity-
induced insulin resistance detected in wild-type mice. In the ad-
ipose tissue of wild-type mice, a dramatic increase in S6K1 ac-
tivation is observed in response to a high fat diet or in genetic
models of obesity, and this is accompanied by an increase in
IRS-1 phosphorylation on S307, S632, and S635 and by attenu-
ation of insulin-induced Akt activation. However, under these
same conditions in 
 
S6K1
 
 
 
/
 
 
 
 mice, these sites on IRS-1 are not
phosphorylated, and Akt remains responsive to insulin. Al-
though this study did not examine S302, an increase in phos-
phorylation of this site has recently been demonstrated in mouse
models of obesity and insulin resistance (Werner et al., 2004).
These results demonstrate that S6K1 is essential to multiple
pathways that render cells unresponsive to insulin, including
those originating from chronic exposure to insulin, FFAs, and
perhaps TNF-
 
 
 
. Interestingly, mice lacking either S6K1 or JNK1
are similarly protected from obesity-induced insulin resistance
and display loss of IRS-1 phosphorylation on S307 (Hirosumi et
al., 2002; Um et al., 2004), a site found to be a direct target of
JNK (Aguirre et al., 2000). It appears that phosphorylation of
S307 and other serines on IRS-1 might, therefore, exhibit cooper-
ation with one another in response to some stimuli. Because
mTOR signaling appears to be required for the effects of several
pathways on IRS-1, it seems likely that there is an initial S6K1-
mediated phosphorylation event, perhaps on S302, that is re-
quired for other serine kinases to subsequently phosphorylate
IRS-1. If this model is correct, this mechanism would prevent any
pathway from blocking insulin signaling when mTOR activity is
low, such as during glucose or amino acid starvation. This would
allow cells, and mTOR, to remain maximally sensitive to the in-
sulin–PI3K–Akt pathway, which is involved in nutrient uptake.
 
Impact on our understanding of human 
disease states
 
As a downstream target, S6K is poised to sense the degree of
activation of mTOR, which is stimulated by both nutrients and
Figure 1. Model of the PI3K–Akt–TSC–TOR pathway and feedback regu-
lation of insulin/IGF-I signaling. (A) Under normal conditions, insulin/IGF-I
engagement of the insulin or IGF-I receptor (IR) leads to Tyr phosphoryla-
tion of IRS proteins and subsequent recruitment and activation of PI3K.
PI3K activity leads to activation of Akt, which phosphorylates and inhibits
many downstream substrates, including BAD, FOXO transcription factors,
GSK3, and tuberin (TSC2). Through these and other targets, Akt activity
stimulates glucose uptake and cell growth and proliferation, and inhibits
apoptosis. Akt-directed phosphorylation of tuberin relieves its inhibition of
TOR, via activation of the small G protein Rheb (not depicted). TOR activa-
tion by this pathway requires the presence of nutrients and results in activa-
tion of S6K and inhibition of 4E-BP1. S6K phosphorylates the ribosomal S6
protein (not depicted) and can feedback and inhibit IRS proteins (see
S6K1: closing the loop section for details). Inhibition of 4E-BP1 relieves its
inhibition of the translation initiation factor eIF4E. (B) Under atypical condi-
tions of constitutive TOR activation, arising from chronic insulin/IGF-I expo-
sure, excess nutrients (e.g., amino acids [AAs] and free fatty acids [FFAs]),
inflammatory cytokines, or genetic loss of specific tumor suppressor genes,
such as TSC2 (encoding tuberin), aberrantly high S6K activity shuts down
insulin/IGF-I signaling. Therefore, although this unregulated TOR activity
leads to constitutive eIF4E activation, it leads to insulin/IGF-I resistance
through down-regulation of IRS protein function. This feedback inhibition
prevents Akt-mediated glucose uptake and regulation of its downstream
substrates. Dashed versus solid lines represent hypothetical signal strength. 
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growth factors (Fig. 1 A). As a critical component of the nega-
tive feedback loop, S6K then has the ability to modify accord-
ingly the level of input from some growth factors, such as insu-
lin and IGF-I. However, under nutritional conditions in which
mTOR is chronically activated, such as in the presence of ex-
cess amino acids or during high fat diets, S6K will constitu-
tively shut down the responsiveness of certain cells to insulin
(Fig. 1 B). This suggests that rapamycin (or, more specifically,
an inhibitor of S6K) might be an effective treatment for certain
metabolic disorders, such as type 2 diabetes, characterized by
insulin resistance (Um et al., 2004).
Chronic activation of mTOR signaling can also result
from genetic loss of certain tumor suppressor genes, including
 
PTEN
 
, 
 
TSC1/2
 
, and 
 
LKB1
 
 (Neshat et al., 2001; Kwiatkowski,
2003; Shaw et al., 2004). Interestingly, mutations in these
genes are associated with the specific tumor syndromes Cow-
den’s disease (
 
PTEN
 
), TSC (
 
TSC1/2
 
), and Peutz-Jegher’s syn-
drome (
 
LKB1
 
), which are all characterized by the develop-
ment of benign tumors classified as hamartomas. Although
aberrant mTOR activation appears to be a common biochemi-
cal link between cells lacking these tumor suppressors, the acti-
vation state of the PI3K–Akt pathway varies. Loss of PTEN
(phosphatase and tensin homologue deleted on chromosome
10), which counters the activity of PI3K, leads to constitutive
activation of Akt (for review see Cantley and Neel, 1999).
However, as discussed above for 
 
TSC1/2
 
, MEFs lacking 
 
LKB1
 
also exhibit some attenuation of Akt activation (Shaw et al.,
2004). This discrepancy might have profound effects on the na-
ture of the tumors that arise in patients with these different syn-
dromes. The overall development of a hamartoma might be the
result of constitutive mTOR activity, but the severity and ma-
lignancy potential of the tumor might depend on the ability to
overcome the feedback inhibition of Akt. The attenuation of
Akt is strongest in the absence of the 
 
TSC
 
 genes, and the inabil-
ity of Akt to phosphorylate and inhibit its downstream sub-
strates other than tuberin, such as specific members of the
FOXO family of transcription factors, GSK3, and Bad, could
limit the proliferation and survival capacity of TSC hamarto-
mas (Fig. 1 B). Consistent with this idea, malignant tumors are
very rare in TSC patients (Kwiatkowski, 2003), whereas in
Cowden’s disease, where loss of PTEN activates Akt indepen-
dently of growth factor signaling, the development of malig-
nant tumors is much more common (Cantley and Neel, 1999).
Because rapamycin relieves this feedback inhibition of
Akt (Harrington et al., 2004; Shah et al., 2004), a difficult ques-
tion in the field is whether this mTOR inhibitor would be bene-
ficial or detrimental to patients with hamartomas exhibiting ab-
errant mTOR activation. Consistent with mTOR activation
driving initial tumor development in these related syndromes,
rapamycin has been proven to be effective at blocking the for-
mation of tumors in rodent models of TSC (Kenerson et al.,
2002). However, it is less clear whether rapamycin would be a
useful treatment once the tumor has already been established,
as is the case in patients diagnosed with TSC. In fact, studies of
 
TSC1/2
 
- and 
 
LKB1
 
-deficient MEFs have demonstrated that un-
der some growth conditions rapamycin actually enhances sur-
vival of cells devoid of these tumor suppressors (Inoki et al.,
2003; Harrington et al., 2004; Shah et al., 2004; Shaw et al.,
2004), and this is likely due to the restoration of critical sur-
vival pathways controlled by Akt. However, these studies are
done on a short-term basis and under very specific conditions.
It seems likely that, although rapamycin’s inhibition of S6K ac-
tivation would eliminate the negative feedback mechanism, it
would also shut down the aberrant activation of eIF4E and cap-
dependent translation. Based on many studies suggesting that
eIF4E is a potent oncogene (e.g., for review see Mamane et al.,
2004; Ruggero et al., 2004; Wendel et al., 2004), it would ap-
pear that the mTOR-dependent activation of eIF4E, through
4E-BP1 phosphorylation, may be at the heart of tumorigenesis
in syndromes exhibiting constitutive mTOR signaling. If this is
true, then long-term treatment with rapamycin would block the
primary cellular process driving tumor growth, irrespective of
Akt activity. Furthermore, it is currently unknown whether the
down-regulation of PDGF receptors observed in TSC-deficient
MEFs is sensitive to rapamycin (Zhang et al., 2003).
It remains to be established whether the state of this
mTOR-dependent feedback mechanism is what delineates the
severity of some tumors and metabolic diseases. However,
studies on this pathway, and the diseases to which it contrib-
utes, underscore the importance of elucidating the complex
wiring of seemingly basic signal transduction pathways. The
days of the linear genetic or biochemical pathway are long past.
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